Evidence map›Paper›PMID 31237717›Full record

ArticleProteins2020

Structural characterization of β-ketoacyl ACP synthase I bound to platencin and fragment screening molecules at two substrate binding sites.

Edward I Patterson, Jeffrey D Nanson, Jan Abendroth, Cassie Bryan, Banumathi Sankaran, Peter J Myler, Jade K Forwood

Open access · greenAbstract read
In one paragraph

Article in Proteins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Edward I PattersonDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas.
Jeffrey D NansonSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-1306-1948
Jan AbendrothSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington.
Cassie BryanSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington.
Banumathi SankaranBerkeley Center for Structural Biology, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California.
Peter J MylerSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington.
Jade K ForwoodSchool of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.ORCID 0000-0003-3267-9997
Center for Infectious Disease Research · USCharles Sturt University · AULawrence Berkeley National Laboratory · USThe University of Queensland · AUThe University of Texas Medical Branch at Galveston · US

Funding

NIAID NIH HHS HHSN272200700057CNIAID NIH HHS HHSN272201200025CNIAID NIH HHS HHSN272201700059C
6 · The paper itself

Abstract

The bacterial fatty acid pathway is essential for membrane synthesis and a range of other metabolic and cellular functions. The β-ketoacyl-ACP synthases carry out the initial elongation reaction of this pathway, utilizing acetyl-CoA as a primer to elongate malonyl-ACP by two carbons, and subsequent elongation of the fatty acyl-ACP substrate by two carbons. Here we describe the structures of the β-ketoacyl-ACP synthase I from Brucella melitensis in complex with platencin, 7-hydroxycoumarin, and (5-thiophen-2-ylisoxazol-3-yl)methanol. The enzyme is a dimer and based on structural and sequence conservation, harbors the same active site configuration as other β-ketoacyl-ACP synthases. The platencin binding site overlaps with the fatty acyl compound supplied by ACP, while 7-hydroxyl-coumarin and (5-thiophen-2-ylisoxazol-3-yl)methanol bind at the secondary fatty acyl binding site. These high-resolution structures, ranging between 1.25 and 1.70 å resolution, provide a basis for in silico inhibitor screening and optimization, and can aid in rational drug design by revealing the high-resolution binding interfaces of molecules at the malonyl-ACP and acyl-ACP active sites.

Indexed as

3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseAmino Acid SequenceAminophenolsBrucella melitensisBrucellosisCatalytic DomainCrystallography, X-RayDrug DesignEnzyme InhibitorsHumansModels, MolecularPolycyclic CompoundsProtein ConformationSubstrate Specificity3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseAminophenolsEnzyme InhibitorsplatencinPolycyclic Compoundsdrug designfatty acid synthesisstructure

Identifiers

PMID31237717
PMCPMC9518911
OpenAlexW2953559918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.